Aging-related Hyperphosphatemia Impairs Myogenic Differentiation and Enhances Fibrosis in Skeletal Muscle
Overview
Authors
Affiliations
Background: Hyperphosphatemia has been related to the development of sarcopenia in aging mice. We describe the intracellular mechanisms involved in the impairment of the myogenic differentiation promoted by hyperphosphatemia and analyse these mechanisms in the muscle from older mice.
Methods: C C cells were grown in 2% horse serum in order to promote myogenic differentiation, in the presence or absence of 10 mM beta-glycerophosphate (BGP) for 7 days. Troponin T, paired box 7 (Pax-7), myogenic factor 5 (Myf5), myogenic differentiation 1 (MyoD), myogenin (MyoG), myocyte enhancer factor 2 (MEF2C), P300/CBP-associated factor (PCAF), histone deacetylase 1 (HDAC1), fibronectin, vimentin, and collagen I were analysed at 48, 72, and 168 h, by western blotting or by immunofluorescence staining visualized by confocal microscopy. Studies in mice were performed in 5- and 24-month-old C57BL6 mice. Three months before sacrifice, 21-month-old mice were fed with a standard diet or a low phosphate diet, containing 0.6% or 0.2% phosphate, respectively. Serum phosphate concentration was assessed by a colorimetric method and forelimb strength by a grip test. Fibrosis was observed in the tibialis anterior muscle by Sirius Red staining. In gastrocnemius muscle, MyoG, MEF2C, and fibronectin expressions were analysed by western blotting.
Results: Cells differentiated in the presence of BGP showed near five times less expression of troponin T and kept higher levels of Pax-7 than control cells indicating a reduced myogenic differentiation. BGP reduced Myf5 about 50% and diminished MyoD transcriptional activity by increasing the expression of HDAC1 and reducing the expression of PCAF. Consequently, BGP reduced to 50% the expression of MyoG and MEF2C. A significant increase in the expression of fibrosis markers as collagen I, vimentin, and fibronectin was found in cells treated with BGP. In mice, serum phosphate (17.24 ± 0.77 mg/dL young; 23.23 ± 0.81 mg/dL old; 19.09 ± 0.75 mg/dL old with low phosphate diet) correlates negatively (r = -0.515, P = 0.001) with the muscular strength (3.13 ± 0.07 gf/g young; 1.70 ± 0.12 gf/g old; 2.10 ± 0.09 gf/g old with low phosphate diet) and with the expression of MyoG (r = -0.535, P = 0.007) and positively with the expression of fibronectin (r = 0.503, P = 0.001) in gastrocnemius muscle. The tibialis anterior muscle from old mice showed muscular fibrosis. Older mice fed with a low phosphate diet showed improved muscular parameters relative to control mice of similar age.
Conclusions: Hyperphosphatemia impairs myogenic differentiation, by inhibiting the transcriptional activity of MyoD, and enhances the expression of fibrotic genes in cultured myoblasts. Experiments carried out in older mice demonstrate a close relationship between age-related hyperphosphatemia and the decrease in the expression of myogenic factors and the increase in factors related to muscle fibrosis.
Aging: A struggle for beneficial to overcome negative factors made by muscle and bone.
Welc S, Brotto M, White K, Bonewald L Mech Ageing Dev. 2025; 224:112039.
PMID: 39952614 PMC: 11893237. DOI: 10.1016/j.mad.2025.112039.
Melatonin ameliorates age-related sarcopenia by inhibiting fibrogenic conversion of satellite cell.
Zhu G, Zhao K, Li H, Wu D, Chen Y, Han D Mol Med. 2024; 30(1):238.
PMID: 39614149 PMC: 11607977. DOI: 10.1186/s10020-024-00998-2.
Manual Therapy Exerts Local Anti-Inflammatory Effects Through Neutrophil Clearance.
Liu H, Yuan S, Zheng K, Liu G, Li J, Ye B J Immunol Res. 2024; 2024:5556042.
PMID: 39534554 PMC: 11557174. DOI: 10.1155/2024/5556042.
Hyperphosphatemia Contributes to Skeletal Muscle Atrophy in Mice.
Heitman K, Bollenbecker S, Bradley J, Czaya B, Fajol A, Thomas S Int J Mol Sci. 2024; 25(17).
PMID: 39273260 PMC: 11395169. DOI: 10.3390/ijms25179308.
The Combination of Lactoferrin and Creatine Ameliorates Muscle Decay in a Sarcopenia Murine Model.
Wu W, Guo X, Qu T, Huang Y, Tao J, He J Nutrients. 2024; 16(12).
PMID: 38931310 PMC: 11207062. DOI: 10.3390/nu16121958.